LLY Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 май 2024 @ 23:00):

Stats
Объем за сегодня	2.77M
Средний объем	3.12M
Рыночная капитализация	718.69B
EPS	$0 ( 2024-04-30 )
Last Dividend	$1.130 ( 2023-11-14 )
Next Dividend	$0 ( N/A )
P/E	111.82
ATR14	$0.732 (0.10%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-15	Sulzberger Gabrielle	Buy	13	Common Stock
2024-04-15	Luciano Juan R	Buy	20	Common Stock
2024-04-15	Johnson Kimberly H	Buy	13	Common Stock
2024-04-15	Hedley Mary Lynne	Buy	13	Common Stock
2024-04-15	Alvarez Ralph	Buy	16	Common Stock

INSIDER POWER
-42.38
Last 100 transactions
Buy: 207 692 \| Sell: 512 083

Объем Корреляция

Длинно: -0.55 (weak negative)

Кратко: 0.72 (moderate)

Signal:(48.938) Neutral

Eli Lilly and Co Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Eli Lilly and Co Корреляция - Валюта/Сырье

0.16
( neutral )

0.09
( neutral )

-0.29
( neutral )

-0.07
( neutral )

Eli Lilly and Co Финансовые показатели

Annual	2023
Выручка:	$34.12B
Валовая прибыль:	$27.55B (80.73 %)
EPS:	$5.82

FY	2023
Выручка:	$34.12B
Валовая прибыль:	$27.55B (80.73 %)
EPS:	$5.82

FY	2022
Выручка:	$28.54B
Валовая прибыль:	$21.91B (76.77 %)
EPS:	$6.93

FY	2021
Выручка:	$28.32B
Валовая прибыль:	$21.01B (74.18 %)
EPS:	$6.15

Financial Reports:

No articles found.

Eli Lilly and Co Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.980 (N/A)	$0.980 (N/A)	$1.130 (N/A)	$1.130 (N/A)	$2.26 (N/A)	$1.130 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Eli Lilly and Co Dividend Information - Dividend Knight

Dividend Sustainability Score: 7.30 - good (72.96%) | Divividend Growth Potential Score: 4.18 - Stable (16.37%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.0114	1972-08-07
Last Dividend	$1.130	2023-11-14
Next Dividend	$0	N/A
Payout Date	2023-12-08
Next Payout Date	N/A
# dividends	207	--
Total Paid Out	$60.68	--
Avg. Dividend % Per Year	1.12%	--
Score	4.67	--
Div. Sustainability Score	7.30
Div.Growth Potential Score	4.18
Div. Directional Score	5.74	--

Next Divdend (Est)
(2024-07-01)

$1.141 Estimate 39.90 %

Dividend Stability

0.80 Good

Dividend Score

4.67

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
1972	$0.0228	0.56%
1973	$0.0494	1.00%
1974	$0.0606	1.32%
1975	$0.0688	1.64%
1976	$0.0782	2.44%
1977	$0.0888	3.01%
1978	$0.103	4.37%
1979	$0.122	4.06%
1980	$0.137	3.79%
1981	$0.144	3.64%
1982	$0.162	4.67%
1983	$0.172	4.79%
1984	$0.186	5.00%
1985	$0.200	4.94%
1986	$0.225	3.28%
1987	$0.250	2.69%
1988	$0.288	2.88%
1989	$0.337	3.15%
1990	$0.412	2.40%
1991	$0.500	2.75%
1992	$0.552	2.60%
1993	$0.604	3.94%
1994	$0.624	4.20%
1995	$0.654	4.01%
1996	$0.684	2.47%
1997	$0.740	2.04%
1998	$0.800	1.16%
1999	$0.920	1.07%
2000	$1.040	1.59%
2001	$1.120	1.22%
2002	$1.240	1.58%
2003	$1.340	2.05%
2004	$1.420	1.99%
2005	$1.520	2.70%
2006	$1.600	2.79%
2007	$1.700	3.25%
2008	$1.880	3.58%
2009	$1.960	4.83%
2010	$1.960	5.47%
2011	$1.960	5.60%
2012	$1.960	4.69%
2013	$1.960	3.96%
2014	$1.960	3.86%
2015	$2.00	2.85%
2016	$2.04	2.46%
2017	$2.08	2.79%
2018	$2.25	2.66%
2019	$2.58	2.25%
2020	$2.96	2.24%
2021	$3.40	2.05%
2022	$3.92	1.44%
2023	$5.65	1.55%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
VGI	Dividend Royal	2024-02-09	Monthly	13	7.36%	8.50
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
GOF	Dividend Royal	2023-11-14	Monthly	18	8.03%	8.50
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
ZTR	Dividend Royal	2024-02-09	Monthly	37	8.35%	8.50
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.171	1.500	6.58	9.88	[0 - 0.5]
returnOnAssetsTTM	0.0960	1.200	6.80	8.16	[0 - 0.3]
returnOnEquityTTM	0.535	1.500	5.16	7.74	[0.1 - 1]
payoutRatioTTM	0.688	-1.000	3.12	-3.12	[0 - 1]
currentRatioTTM	1.354	0.800	8.23	6.58	[1 - 3]
quickRatioTTM	0.677	0.800	-0.721	-0.577	[0.8 - 2.5]
cashRatioTTM	0.132	1.500	-0.376	-0.564	[0.2 - 2]
debtRatioTTM	0.410	-1.500	3.17	-4.75	[0 - 0.6]
interestCoverageTTM	17.51	1.000	4.62	4.62	[3 - 30]
operatingCashFlowPerShareTTM	4.08	2.00	8.64	10.00	[0 - 30]
freeCashFlowPerShareTTM	-4.22	2.00	-2.11	-4.22	[0 - 20]
debtEquityRatioTTM	2.05	-1.500	1.817	-2.73	[0 - 2.5]
grossProfitMarginTTM	0.809	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.230	1.000	7.39	7.39	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.140	1.000	-0.332	-0.332	[0.2 - 2]
assetTurnoverTTM	0.562	0.800	9.59	7.67	[0.5 - 2]
Total Score				7.30

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	113.99	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.535	2.50	6.89	7.74	[0.1 - 1.5]
freeCashFlowPerShareTTM	-4.22	2.00	-1.406	-4.22	[0 - 30]
dividendYielPercentageTTM	0.604	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	4.08	2.00	8.64	10.00	[0 - 30]
payoutRatioTTM	0.688	1.500	3.12	-3.12	[0 - 1]
pegRatioTTM	-0.672	1.500	-7.81	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.102	1.000	9.94	0	[0.1 - 0.5]
Total Score				4.18

Eli Lilly and Co

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.